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ABSTRACT 
Objective: To observe the clinical outcomes on usage of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers 
(ARBs) in type 2 diabetic nephropathy patients. 
Methods: A total 70 patients diagnosed with diabetic nephropathy were treated with ACEIs or ARBs were enrolled in this study. The data was 
collected from the out patients and the physician. A data collection form was used for collecting patient data. The form was used to record the 
details of patient’s demographics, history of diabetes mellitus, duration of diabetes mellitus co morbidities, food habits and laboratory parameters 
such as serum creatinine, HbA1c and all the relevant things. The study has obtained ethical clearance from the institution ethics committee (IEC). 
Results: The study showed middle aged patients were more prone to diabetes and pre-existing hypertension is a major risk factor for diabetic 
nephropathy. Majority of the patients had long duration of diabetes mellitus which indicates the strong relation between duration of diabetes 
mellitus with diabetic nephropathy. Compared to ACE inhibitors, ARBs decreased the level of renal parameters. This reveals the better reno-
protective effect of ARBs over ACE inhibitors. ARBs had more beneficial effects in reducing the major risk factor like proteinuria in diabetic 
nephropathy. A considerable reduction in HbA1c values were also observed in patients using ARBs. 
Conclusion: While comparing the improvement in proteinuria and the laboratory outcomes, ARBs were beneficial relatively to the ACEs in patients 
with diabetic nephropathy. 
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INTRODUCTION 
Diabetes mellitus is a group of metabolic disorders characterized by 
hyperglycemia. It is associated with abnormalities in carbohydrates, 
fat and protein metabolism and results in chronic complications 
including micro vascular and macro vascular disorders [1]. India has 
a high prevalence of diabetes mellitus and the numbers are 
increasing at an alarming rate. In India alone, diabetes is expected to 
increase from 40.6 million in 2006 to 79.4 million by 2030 [2]. The 
prevalence of type 2 diabetes is 4-6 times higher in urban than in 
rural areas [3]. The risk factors peculiar for developing diabetes among 
Indian include high familial aggregation, central obesity, insulin 
resistance and life style changes duo to urbanization. Simple 
interventional strategies like “Eat less, Eat on time and Walk more” can 
go a long way in preventing these chronic disorders among present as 
well in future generation. There are 3 main type of diabetes: Type 1, 
Type 2 and Gestational diabetes mellitus. Type 2 is the most common 
form of diabetes and accounts for 90 to 955 of diabetes cases. Chronic 
hyperglycemia without proper management can also lead to various 
short term and long term secondary complications, both of small and big 
vascular nature may be determined as the main cause of mortality and 
morbidity in type 2 diabetic patients all over the world. 
The long term effects of diabetes mellitus include progressive 
development of the specific complication of retinopathy with 
potential blindness, nephropathy that may lead to renal failure and 
neuropathy with risk of foot ulcers, amputation [4]. Complication of 
diabetes can be mainly divided into two: Micro vascular 
(Retinopathy, Neuropathy and Nephropathy) and Macro vascular 
(Cardiovascular disease and Peripheral vascular disease). 
Diabetic nephropathy is the important cause of morbidity and 
mortality and affects almost 20-30 percent of patients with diabetes. 
It is also a leading cause of kidney failure in India and is seen in early 
stage with low level of albumin (micro albuminuria) in urine.  
Clinical hallmark of diabetic nephropathy include a progressive 
increase in urinary albumin excretion and a decline in glomerular 
filtration rate (GFR), which occur in association with an increase in 
blood pressure, ultimately leading to end stage renal failure.  
The Angiotensin II receptor blockers (ARBs) represent a new class 
of antihypertensive agent that was developed to overcome several 
deficiencies of ACE inhibitors, it may offer complete angiotensin II 
inhibition by interacting selectively with the receptor site [5]. All the 
7 drugs in this class are approved by the food and drug 
administration for the treatment of hypertension either alone or in 
combination with other drugs. Unable uses include the treatment of 
congestive heart failure and diabetic nephropathy [6]. 
ACEIs decrease in GFR often increase serum creatinine 
concentration, and small increase should be anticipated. If large 
increases occur, ACE inhibitor therapy should be stopped or the 
dose reduced [7]. Some of the beneficial effects of bradykinin such as 
vasodilatation (which enhance BP lowering), regression of myocyte, 
hypertrophy and fibrosis and increased levels of tissue plasminogen 
activator are not present with ARB therapy [8]. 
In diabetes, both metabolic and hemodynamic factors interact to 
modify the glomerular microcirculation, creating an environment 
conductive to progressive glomerular injury. Patients with poor 
glycemic control show a greater reduction in intrarenal vascular 
resistance after blockade of RAS than that seen in subject with good 
metabolic control. Therefore with the wide spread use of agent that 
interrupts the RAS as first-line treatment in diabetic patients is at 
risk of diabetic nephropathy [9]. 
India is the diabetic capital of the world and hence the diabetic 
nephropathy management in India needs an assessment. ACEIs and 
ARBs are the more frequently used drugs in the management of 
diabetic nephropathy in India and hence a comparative study of 
both of them is needed.  
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The objective of the study was to find out the efficacy of ACEIs or 
ARBs reducing albuminuria in diabetic nephropathy patients. To 
find out the most preferable agent out of these two and to compare 
their blood pressure lowering effect. Along with reno-protecive 
effects, effects on hyperglycemia and proteinuria also have to 
compare for finding out the comparative effectiveness of two drugs. 
MATERIALS AND METHODS 
Study site 
The study was conducted at Nirmala Hospital at Calicut, a private 
tertiary level referral hospital in south Malabar region of Kerala. 
Study period 
Comparative observational study over 10 mo period. 
Study population 
Total population-70 patients 
Study criteria 
Inclusion criteria 
• Type 2 diabetic nephropathy patients who were on treatment 
with ACE inhibitors and ARBs. 
• Age group: 18-80years. 
• Outpatients. 
• Patients with or without proteinuria were included. 
• Patient with or without hypertension were included. 
• Patients with other micro vascular disease like retinopathy, 
neuropathy, and foot ulcer were also included. 
Exclusion criteria 
• Type 1 diabetic patients were excluded. 
• Pregnant women and pediatric patients were excluded. 
Designing of data collection form 
Reply to comment a3: The data collection form was for collecting the 
demographic as well as the medication details and lab results only. 
A data collection form was used for all collecting patient data. This 
form containing the details of patient’s demographics such as name, 
age, sex, history of diabetes mellitus, duration of diabetes mellitus, 
co-morbidities, food habit, complications and laboratory parameters 
such as creatinine, HbA1c, protein to creatinine ratio and all the 
relevant things. 
Data collection 
The data was collected from the out patients, physicians and other 
healthcare professionals. 
• By direct interview with patients and care givers. 
• From the out-patient files and prescriptions. 
This study included 70 patients diagnosed with type 2 diabetic 
nephropathy who were on treatment with ACEI or ARB. They were 
grouped according to their therapy into 2 groups as the patients 
taking ACEI only or ARB only and were distributed in equal 
proportion (35 each). The patient’s follow up was done every month, 
up to 10 mo. The main monitoring parameters like protein to 
creatinine ratio, blood pressure, Creatinine, urea, Hb, HbA1c, blood 
sugar level and potassium were monitored and recorded during the 
study period. 
Data analysis 
The recorded data was analyzed statistically. Student’s T-test was 
used to compare quantitative and qualitative variables respectively. 
Data was expressed as mean and standard error. After six month of 
treatment, protein excretion and BP reduction were calculated as 
the difference between final and baseline values for each patient and 
compared all the basic parameters in two groups. 
Ethical committee approval and patients caregivers or patients 
consent was taken before data collection. 
RESULTS 
In this study patient demographic data’s were collected. The patients 
were classified according to age, gender, duration of diabetes 
mellitus and food habit. 
 
 
Fig. 1: Gender distribution among individual groups (N=70) 
 
In patients who were treated with ACE inhibitors, out of 35 
patients 63 %(N=22) were males and 37.14 %(N=13) were 
females. In patients who were treated with ARB out of 35 




Fig 2: Age distribution among individual groups (N=70) 
 
The most prominent age group in patients who were treated with 
ACEI were 51-60 y, which constituted 45.71% (N=16) of the patient 
population, followed by 41-50years, which constitute 25.71%(N=9), 
followed by 61-70 y which constitute 17.14%(N=6), followed by 71-
80 y constitute 8.57%(N=3) and age group of 31-40 y constitute 
2.86%(N=1). There were no patients below 30 y in ACEI treated 
patients. 
In patients who were treated with ARB, the most prominent age 
groups were 41-50 y and 51-60years, both constitute similarly as 
31.43%(N=11), followed by 61-70 y, which constitute 
28.57%(N=10) and least number of patients were seen in the age 
groups 71-80 and 20-30 y which constitute 5.71%(N=2) and 
2.86%(N=1) respectively. There were no patients in the age group 
31-40years in ARB treated patients. 
This reveals that middle aged populations suffer more from diabetic 
nephropathy. 
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Fig. 3: Food habit among individual groups (N=70) 
 
Out of 35 patients who were treated with ACE inhibitors, 11.43 
%(N=4) were vegetarians and 88.57 %(N=31) were non-vegetarian. 
Out of 35 ARB treated patients, 28.57 % 
(N=10) were vegetarian and 71.43 %(N=25) were non-vegetarians. 
 
 
Fig. 4: Duration of diabetics among individual groups (N=70) 
 
In patients who were treated with ACEI, the patients who had 
duration of diabetes mellitus between 10-15 y had more incidence 
i.e., 34.29%(N=12) of diabetic nephropathy. The patients in the 15-
20 and 5-10 duration had the incidence of diabetic nephropathy22.8 
%(N=8) and 20 %(N=7) respectively. 14.29 %(N=5) patients were 
prone to diabetes mellitus between 0-5 y.5.71 % (N=2) of patients 
had diabetes mellitus since 20-25 followed by 2.86 %(N=1) of 
patients in 25-30years. 
In patient who were treated with ARB, the patient who had duration 
of diabetes mellitus between 5-10years i.e., 57.14(N=14), followed 
by 28.57 %(N=10) between 15-20 y duration and 17.14 %(N=6) 
between 10-15 y duration. 14.29 %(N=5) patients had duration of 
diabetes mellitus between 0-5 y. 
Long standing diabetes mellitus is associated with increased 
prevalence of micro vascular disease. Duration of diabetes was one 
of the most important risk factor for diabetic nephropathy. 
 
 
Fig. 5: Distribution of co-morbidities in individual group (N=70) 
 
The most prevalent co-morbidity seen in diabetic nephropathy 
patients who were treated with ACEI were hypertension (HTN) 
which accounts for 48.57 %(N=17), followed by those suffering from 
both retinopathy and neuropathy42.86 %(N=15). Patients with foot 
ulcer were 14.29 %(N=5) and patients with neuropathy only were 
11.43 %(N=4). Patients with retinopathy only were 5.71 %(N=2). 
The most prevalent co-morbidity seen in patients who were treated 
with ARB was hypertension which accounts for 60 %(N=21), 
followed by patients with both retinopathy and neuropathy account 
for 28.57 %(N=10). Patients with retinopathy only were 14.29 
%(N=5) and neuropathy only and foot ulcer only were 2.86 %(N=1) 
each. 
Here the most prevalent co-morbidity is hypertension in two groups. 
It reveals that pre-existing hypertension is a risk factor for 
developing diabetic nephropathy. 
 
Table 1: Drug usage in diabetic nephropathy patients (N=70) 
Drugs Total (%) (N=70) ACEI (%) (N=35) ARB (%) (N=35) 
Insulin 20% 22.86% 17.14% 
Oral hypoglycemic 52.86% 57.14% 48.57% 
Insulin+Oralhypoglycemic drugs 27.14% 20% 34.29% 
Lipid lowering drugs 41.43% 34.29% 48.57% 
Other antihypertensives 62.86% 60% 65.71% 
 
The current recommendation for patients with diabetes is the 
treatment with an ACE inhibitors or ARB to reduce the risk of 
nephropathy [10]. Combination of an ACE inhibitor and ARB may 
potentially reduce the progression of diabetic nephropathy more 
than either agent alone [11]. 
Out of 70 patients 52.86 %(N=37) used Oral hypoglycemic (OHGs) 
as anti-diabetic drug, followed by insulin+oral hypoglycemic27.14 
%(N=19) and remaining 20 %(N=14) were used insulin alone as 
anti-diabetic agent. 
In patients who were treated with ACEIs 57.14 %(N=20) used OHGs 
as anti-diabetic agent, followed by insulin 22.86 %(N=8), and 
remaining 20 %(N=7) used both insulin and OHGs. 
In patients who were treated with ARB more number of patients 
used OHGs as anti-diabetic agent as in ACE inhibitors treated 
patients i.e., 48.57 %(N=17), followed by 34.29 %(N=12) used both 
insulin and OHGs, and remaining 17.14 %(N=6) used insulin as anti-
diabetic agent. 
Out of 70 patients 41.43 %(N=29) patients used lipid lowering 
drugs, which is 34.29 %(N=12) and 48.57 %(N=17)respectively in 
patients who were on ACEI and ARB. 
Out of 35 patients who were treated with ACE inhibitors 92.31 % 
(N=24) were seen with decreased P/C ratio after 6 mo. The patient 
who were treated with ARB 94.29 % (N=33) patients were seen with 
decreased p/c ratio after 6 mo, so improved microalbunuria. 
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Table 2: Baseline clinical characteristics of patients (N=70) 
Variables ACEI group (mean±S.E.) ARB group (mean±S.E.) P value 
Urea(10-44 mg) 59.571±4.920 52.571±4.524 0.1468 
Keratinize(0.4-1.4 mg/dl) 2.89±0.282 2.286±0.217 0.0256* 
SBP(120 mmHg) 158.257±4.775 169.714±4.444 0.04* 
DBP(80 mmHg) 87.143±1.767 86.57±1.687 0.4099 
K+(3.5-5.1mEq/l) 4.834±0.122 4.888±0.118 0.3536 
P/C ratio 2.528±0.278 2.438±0.2219 0.7991 
Hb(12-15g/dl) 10.44±0.391 9.806±0.293 0.1971 
RBS(70-140 mg/dl) 197.886±9.363 203±11.981 0.3838 
HbA1c (4-6%) 6.861±0.221 7.145±0.331 0.3652 
*P<0.05 denotes significant difference, There was significant difference in the SBP and creatinine between the groups. 
 
Table 3: % Patients with improved clinical outcomes after 6 mo 
Variables ACEI group ARB group 
Urea (10-45 mg/dl) 48.57% 54.29% 
Creatinine(0.4-1.4 mg/dl) 40% 54.29% 
SBP(120 mmHg) 74.29% 85.71% 
DBP(80 mmHg0 68.57% 91.43% 
K+(3.5-5.5mEq/l) 48.57% 60% 
Hb(12-15g/dl) 34.29% 45.71% 
Sugar(70-140 mg/dl) 65.71% 62.86% 
HbA1c (4-6%) 65.71% 71.43% 
P/C ratio 92.31% 94.29% 
Out of 35 patients who were treated with ACE inhibiters group 48.57 %(N=17) were seen with decreased urea level after 6 mo. In ARB group 54.29 
%(N=19) patients were seen with decreased urea level after the 6th
 
CONCLUSION 
 month. So improved urea level was observed in ARB group after 6 mo. 
• Middle aged patients were more prone to diabetic nephropathy 
in this study group. Pre-existing hypertension and protein urea were 
the major risk factors in the progression of diabetic nephropathy. 
• Majority of patients had long duration of DM which indicates the 
strong relation between duration of DM with diabetic nephropathy. 
• Compared to ACE inhibitors, ARBs showed decrease in the levels 
of renal parameters such as blood urea, Creatinine and potassium. 
This study reveals that ARBs have favorable effect than ACEIs in 
treating diabetic nephropathy. 
• Hemoglobin level was also increased in patients who were 
treated with ARBs compared to ACEIs, which reveals that ARB show 
better renoprotective effects than ACEIs.  
• Blood sugar levels and HbA1c levels decreased more with ARB 
than ACE inhibitors.  
• In patients with type 2 diabetes the risk of diabetic 
complications was strongly associated with previous hyperglycemia. 
Any reduction in HbA1c is likely to reduce the risk of complications. 
Limitations 
1. Short duration of the study 
2. Time duration of consumption of ACEIs/ARBs were not taken into 
account. 
ABBREVATION 
ADA-American Diabetes Association, ACEIs-Angiotensin Converting 
Enzyme, ARBs-Angiotensin Receptor Blockers, BP-Blood Pressure, 
CKD-Chronic kidney Disease, CVD-Cardiovascular disease, DM-
Diabetes Mellitus, DCCB-Dihydropyridine Calcium Channel Blockers, 
GDM-Gestational Diabetes mellitus, HbA1c-Glycosylated 
hemoglobin, GFR-Glomerular Filtration Rate, LDL-Low Density 
Lipoprotein, MAU-Microalbuminuria, RAAS-Renin Angiotensin 
Aldosterone System, UAE-Urinary Albumin Excretion 
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